A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This study is an open label, single dose, single site, randomized, cross over study that will
assess nasal deposition of radioactivity following nasal inhalation of a ciclesonide
radiolabeled solution via a novel nasal Metered Dose Inhaler (MDI) and of a mometasone
furoate monohydrate radiolabeled suspension via an aqueous nasal spray in approximately 10-14
patients with symptomatic allergic rhinitis, aged 18-65 years.